Bosutinib versus placebo for autosomal dominant polycystic kidney disease

Vladimir Tesar, Kazimierz Ciechanowski, York Pei, Irina Barash, Megan Shannon, Ray Li, Jason H. Williams, Matteo Levisetti, Steven Arkin, Andreas Serra

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


Overactivation of Src has been linked to the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). This phase 2, multisite study assessed the efficacy and safety of bosutinib, an oral dual Src/Bcr-Abl tyrosine kinase inhibitor, in patients with ADPKD. Patients with ADPKD, EGFR$60 ml/min per 1.73 m2, and total kidney volume $750 ml were randomized 1:1:1 to bosutinib 200 mg/d, bosutinib 400 mg/d, or placebo for #24 months. The primary endpoint was annualized rate of kidney enlargement in patients treated for $2 weeks who had at least one postbaseline magnetic resonance imaging scan that was preceded by a 30-day washout (modified intent-to-treat population). Of 172 enrolled patients, 169 received at least one study dose. Per protocol amendment, doses for 24 patients who initially received bosutinib at 400 mg/d were later reduced to 200 mg/d. The annual rate of kidney enlargement was reduced by 66% for bosutinib 200 mg/d versus placebo (1.63% versus 4.74%, respectively; P=0.01) and by 82% for pooled bosutinib versus placebo (0.84% versus 4.74%, respectively; P,0.001). Over the treatment period, patients receiving placebo or bosutinib had similar annualized EGFR decline. Gastrointestinal and liver-related adverse events were the most frequent toxicities. In conclusion, compared with placebo, bosutinib at 200 mg/d reduced kidney growth in patients with ADPKD. The overall gastrointestinal and liver toxicity profile was consistent with the profile in prior studies of bosutinib; no new toxicities were identified. ( NCT01233869).

Original languageEnglish
Pages (from-to)3404-3413
Number of pages10
JournalJournal of the American Society of Nephrology : JASN
Issue number11
StatePublished - Nov 2017


Dive into the research topics of 'Bosutinib versus placebo for autosomal dominant polycystic kidney disease'. Together they form a unique fingerprint.

Cite this